The guidelines now specify the process for the regulatory acceptance of NAMs, detailing how developers can engage with EMA's Innovation Task Force and submit data for evaluation.
This shift towards NAMs is significant as it can lead to reduced reliance on animal testing, promoting more ethical practices in medicine development and aligning with the principles of the '3Rs'.
Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.
The EMA has introduced guidelines promoting the regulatory acceptance of new approach methodologies (NAMs) that aim to replace, reduce, and refine traditional animal testing. This initiative encourages developers to interact with EMA through informal discussions about their NAMs and aids in assessing their readiness for regulatory decision-making.
What changed: The guidelines now specify the process for the regulatory acceptance of NAMs, detailing how developers can engage with EMA's Innovation Task Force and submit data for evaluation.
Why it matters: This shift towards NAMs is significant as it can lead to reduced reliance on animal testing, promoting more ethical practices in medicine development and aligning with the principles of the '3Rs'.
Practical implication: Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.
Published from the regulator source ingestion pipeline after PV impact triage.
Healthcare professionals should not initiate treatment with Avacopan Vifor for new patients and must review existing patients' treatment plans to ensure safe transitions to alternative therapies.
Manufacturers must familiarize themselves with the new procedure, including creating an EMA account and understanding the timelines for submitting the required briefing documents according to the established timetable for 2025 and 2026.
Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.
Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.
